What Framingham Heart Study does

The Framingham Heart Study (FHS) is a longitudinal cardiovascular cohort study launched in 1948 by what is now the National Heart, Lung, and Blood Institute (NHLBI) and administered through Boston University Chobanian & Avedisian School of Medicine since 1971. It enrolls more than 15,000 participants across three generations — the Original Cohort, Offspring Cohort, Generation 3, and Omni cohorts — with over 2 million biosamples and 78+ years of continuous follow-up. Core research output includes standardized phenotyping, adjudicated cardiovascular and mortality events, multi-omics data (genomics, metabolomics, proteomics, epigenomics), iPSC lines, and tissue repositories (LEGACY heart-tissue biobank, brain tissue program).

The study's product surface is a research platform rather than a commercial offering. Public deliverables include the Framingham Risk Score calculators (freely available for cardiovascular disease, stroke, atrial fibrillation, heart failure, hypertension, diabetes, fatty liver disease, and other conditions), peer-reviewed publications, and an extensive bibliography. For qualified academic and clinical researchers, FHS distributes phenotypic data via BioLINCC, genotypic/phenotypic data via dbGaP, iPSC lines via WiCell and BU CReM, and bespoke data/biospecimens via the FHS Research Application (FHS ResApp) system, subject to IRB approval and Data and Materials Distribution Agreements.

The business model is grant-funded and academic. Primary revenue is the NHLBI core contract (currently 75N92019D00031, $38M over six years, awarded 2019), supplemented by NIH and American Heart Association research grants (e.g., the $26.56M FHS Brain Aging Program, the $3.3M AHA/Bill Gates brain-health initiative, the $495K Doris Duke Clinical Scientist Development Award). Data and material access fees are cost-recovery only. The customer base is global academic and clinical investigators, with primary segments being academic/clinical researchers and public-health organizations such as NHLBI and AHA that translate FHS findings into guidelines and risk-prediction models.

Name

Framingham Heart Study

Legal name

Framingham Heart Study

Website

https://framinghamheartstudy.org

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

11–50 employees

Short description

The Framingham Heart Study is a 78-year, NIH/NHLBI-funded longitudinal cardiovascular cohort study administered by Boston University, following 15,000+ participants across three generations and providing validated phenotypic, genetic, and biospecimen data to global academic and clinical researchers.

Ownership category

akta.pro rank

Product category

Cardiovascular Epidemiology Research

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Social Sciences and Humanities (54172)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Data Linkage, Registries & Longitudinal Cohort Surveillance (HLAJANAM)

akta.pro secondary industries

Preventive Cardiology & Lipidology (HLAKABAF), Population Genomics & Preventive Precision Health Programs (HLAAANAL), Behavioral Risk & Health Survey Surveillance (HLAJANAD), Health Statistics & Reporting (National/State/Local Indicators) (HLAJAJAC)

Keywords

• Longitudinal cohort study
• Cardiovascular epidemiology research
• Clinical risk calculators
• Biorepository biospecimen services
• Population health data access

Headquarters

HQ city

Framingham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

1. NIH/NHLBI Core Contract: Primary funding from the National Heart, Lung, and Blood Institute (NHLBI) of the NIH under contract 75N92019D00031. The study has been continuously funded since 1971 through Boston University, with recent contracts including a six-year $38 million award for Offspring and Omni 1 cohorts.
2. NIH Research Grants: Investigator-initiated research grants from NIH and other agencies supporting ancillary studies and specialized research programs, including the $26.56 million FHS Brain Aging Program and $3.3 million brain health initiative (AHA/Bill Gates).
3. American Heart Association Funding: AHA-funded research grants and awards supporting cardiovascular epidemiology research, including investigator awards and research grants to FHS researchers.
4. Data Access Fees: Fee-based data and materials distribution through the FHS Service Center for approved research applications, covering processing and distribution costs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

The Framingham Heart Study is a multi-generational longitudinal cardiovascular cohort study that continuously follows more than 15,000 participants across three generations (Original, Offspring, Generation 3, and Omni cohorts) and collects phenotypic, genetic, and omics data along with over 2 million biosamples. It distributes de-identified phenotypic and genetic datasets, iPSC lines, and heart and brain tissue to qualified researchers through dbGaP, BioLINCC, WiCell/CReM, and the FHS Research Application system, and provides the Framingham Risk Score calculators for public cardiovascular risk assessment.

Product overview

The Framingham Heart Study is a landmark longitudinal epidemiological research study rather than a commercial product. It operates as a research platform providing data, risk assessment tools, and biospecimens to the scientific community. Core offerings include the ongoing multi-generational study with over 15,000 participants and 2 million biosamples, the Framingham Risk Score calculator suite for cardiovascular risk assessment, FHS phenotypic datasets accessible via the Research Application system, and iPSC/LEGACY biobank resources for cellular research. Additional offerings include the Dawber Scholarship program, brain tissue resources, and community engagement through the 'Many Cultures, One Heart' art initiative. Data access is managed through dbGaP, BioLINCC, and the FHS Research Application.

Differentiator

Problem solved

Functional benefit

Brands

• LEGACY: The Lifelong Endowment for Genomic and Cellular DiscoverY (LEGACY) - a tissue biobank program enabling heart tissue donation from FHS participants after death to facilitate research on heart health and disease.

Quantifiable outcome

• FHS research has contributed to the development of cardiovascular risk prediction models used worldwide in clinical practice
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core, major and supporting.

• Boston University Chobanian & Avedisian School of MedicinecoreStrategic or Co-development Partner · 1 January 1971Administrative home of FHS since 1971, providing institutional infrastructure, faculty investigators, research staff, and operational support for study administration and scientific direction.
• Jackson Heart StudymajorStrategic or Co-development PartnerCollaboration under the AHA Cardiovascular Genome Phenome Study (CVGPS), bringing together FHS and Jackson Heart Study data. Partner institutions include Jackson State University and Tougaloo College alongside UMMC.
• University of Mississippi Medical CentermajorStrategic or Co-development PartnerAcademic coordinating center for the Jackson Heart Study in the CVGPS collaboration with FHS, jointly funded by AHA and NIH.
• American Heart Association (AHA)majorStrategic or Co-development PartnerStrategic partner through CVGPS collaboration and co-funder of brain health research initiatives including $3.3M brain health and dementia technology research center at Boston University.
• dbGaP (Database of Genotypes and Phenotypes)coreTechnology or IntegrationNIH repository for FHS genetic and genomic data, making genotypic and phenotypic data available to qualified researchers globally without requiring separate FHS research application.
• BioLINCC (NHLBI Biological Specimen and Data Repository)coreTechnology or IntegrationNHLBI repository for FHS phenotypic data including Original Cohort, Offspring Cohort, and Generation 3 Cohort datasets. Available to qualified researchers with associated access procedures.
• WiCell Research InstitutecoreChannel Partner/ Reseller/ DistributorDistribution partner for FHS iPSC lines (68 lines from Next Gen collection). FHS partnered with WiCell to make iPSC lines available to investigators worldwide.
• Boston University Center for Regenerative Medicine (CReM)coreTechnology or IntegrationPartnered with BU CReM for derivation and banking of FHS iPSC lines. CReM iPSC Core maintains state-of-the-art frozen iPSC lines available to BU and external investigators.
• Friends of the Framingham Heart StudysupportingGTM or Marketing PartnerNon-profit organization supporting FHS through community engagement, scholarships (Dawber Essay Contest), and public outreach programs including the 'Many Cultures, One Heart' art project.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• UK Biobank: Large-scale prospective cohort of ~500,000 participants with deep phenotypic, genomic, and imaging data. The most direct global comparison to FHS as a population-based longitudinal research platform for chronic disease research.
• Jackson Heart Study: NIH-funded longitudinal cardiovascular cohort study of African American adults in Jackson, MS — a direct FHS peer and current CVGPS collaboration partner, with comparable study design and adjudicated cardiovascular outcomes.
• Multi-Ethnic Study of Atherosclerosis (MESA): NHLBI-sponsored longitudinal cohort study of subclinical cardiovascular disease across four racial/ethnic groups. Shares FHS' cardiovascular epidemiology focus while extending diversity, making it a key adjacent cohort study.
• All of Us Research Program: NIH flagship precision medicine cohort aiming to engage 1M+ diverse U.S. participants with genomic, EHR, and survey data. Competes with FHS for the same NIH-funded longitudinal research mandate at a much larger and more diverse scale.
• ARIC Study (Atherosclerosis Risk in Communities): Long-running NHLBI-sponsored prospective cohort study of atherosclerosis and cardiovascular disease across four U.S. communities — directly comparable cardiovascular epidemiology platform to FHS.
• Nurses' Health Study: Iconic longitudinal cohort of U.S. female nurses begun in 1976 with extensive lifestyle, biomarker, and disease outcome data. Comparable longitudinal design and ancillary study infrastructure to FHS.
• deCODE Genetics: Iceland-based population genomics company (now Amgen subsidiary) using whole-genome sequencing of a national cohort to drive disease gene discovery. Comparable in combining population-scale genomics with longitudinal health data for cardiovascular and metabolic research.
• Rotterdam Study: Long-running Dutch prospective cohort study focused on cardiovascular, neurological, and chronic diseases in the elderly — directly comparable multi-disease longitudinal research platform to FHS.
• Cardiovascular Health Study (CHS): NHLBI-funded longitudinal cohort study of cardiovascular disease risk in adults aged 65+ — directly comparable to FHS in scope, sponsor, and adjudicated cardiovascular outcome focus.

Regional players

• Finnish Institute for Health and Welfare Biobank (THL Biobank): Large national biobank leveraging Finland's comprehensive health records and population genetics for cardiovascular and chronic disease research. Comparable as a population-scale data and biospecimen resource, though geographically distinct.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/framingham-heart-study

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Framingham Heart Study